CUE
Cue BiopharmaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The constructive case is that Cue preserves Nasdaq listing, avoids a disorderly financing outcome, and continues extracting non-dilutive value from collaborations such as ImmunoScape and BI, leaving the equity materially above today's distressed micro-cap level if funding pressure eases [#8-K-2026-04-13] [#10-K-2026-03-16].
Posture
Defensive
Lead driver
Momentum
What changed
2 setup hits (3d) with net bullish as of 2026-06-03.
What can break
Collaboration-related cash inflows, including ImmunoScape timing, may not be sufficient to offset broader funding needs [#10-K-2026-03-16].
Momentum
99
Value
41
Sentiment
0
Setup hits (3d)
2 · Net Bullish
AI TargetsBase $0.38 · Bull $0.85 · Bear $0.14
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $4.00
Why
Momentum99 · Δ7d -0.3
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
99
34% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 98.7 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$115.79M
Beta
1.49
Shares Out
78.74M
P/E (TTM) · Derived
-2.0
P/S (TTM)
4.24
P/FCF (TTM) · Derived
-4.25
Rev YoY
-35.6%
EPS YoY
+56.3%
Gross Margin
-
Op Margin
-537.5%
Net Debt
-$18.13M
Current Ratio
1.66
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology